Background Experimental and clinical evidence supports the role of inflammation in
atherosclerosis and its complications. Colchicine is an orally administered, potent antiinflammatory …

Aims Ivabradine, a new I f inhibitor which acts specifically on the pacemaker activity of the
sinoatrial node, is a pure heart rate lowering agent. Ivabradine has shown anti-ischaemic and …

A growing body of evidence from clinical trials and epidemiological studies has identified
elevated resting heart rate as a predictor of clinical events. Proof of direct cause and effect is …

Aims Heart rate reduction is the cornerstone of the treatment of angina. The purpose of this
study was to explore the prognostic value of heart rate in patients with stable coronary artery …

ContextHigh-density lipoprotein (HDL) cholesterol is an inverse predictor of coronary
atherosclerotic disease. Preliminary data have suggested that HDL infusions can induce …

ContextPrior intravascular ultrasound (IVUS) trials have demonstrated slowing or halting of
atherosclerosis progression with statin therapy but have not shown convincing evidence of …

Background Inhibition of cholesteryl ester transfer protein (CETP) has been shown to have
a substantial effect on plasma lipoprotein levels. We investigated whether torcetrapib, a …

Background Patients with elevated triglyceride levels are at increased risk for ischemic
events. Icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, lowers triglyceride …

Background Cardiovascular morbidity and mortality are higher among patients with type 2
diabetes, particularly those with concomitant cardiovascular diseases, than in most other …

Background In observational analyses, higher levels of high-density lipoprotein (HDL)
cholesterol have been associated with a lower risk of coronary heart disease events. However, …